Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first ...
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products ...
Stocktwits on MSN1d
Tonix Pharma Dominates Retail Biotech Buzz After 1-for-100 Reverse Split, Sentiment Turns Neutral Amid VolatilityTonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade ...
CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a clinical-stage biotech company with a market capitalization of $28 million, announced today positive outcomes from its Phase 1 ...
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced ...
Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product DevelopmentTonix is Preparing for Potential Launch ...
Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 54.47%, which has investors questioning if this is right ...
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tonix ...
Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback